Cytokinetics Stock In The News
| CYTK Stock | USD 52.22 0.20 0.38% |
Our overall analysis of Cytokinetics' news coverage and content from conventional and social sources shows investors' bearish mood towards Cytokinetics. The specific impact of Cytokinetics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Cytokinetics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Cytokinetics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Cytokinetics Backtesting and Cytokinetics Hype Analysis. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.
Cytokinetics |
Cytokinetics Today Top News and Investor Outlook
Cytokinetics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Cytokinetics and other traded companies coverage with news coverage. We help investors stay connected with Cytokinetics headlines for the 28th of November to make an informed investment decision based on correlating the impacts of news items on Cytokinetics Stock performance. Please note that trading solely based on the Cytokinetics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Cytokinetics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Cytokinetics earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Cytokinetics that are available to investors today. That information is available publicly through Cytokinetics media outlets and privately through word of mouth or via Cytokinetics internal channels. However, regardless of the origin, that massive amount of Cytokinetics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cytokinetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cytokinetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cytokinetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cytokinetics alpha.
Cytokinetics Largest EPS Surprises
Earnings surprises can significantly impact Cytokinetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2015-07-29 | 2015-06-30 | -0.23 | -0.27 | -0.04 | 17 | ||
2019-08-08 | 2019-06-30 | -0.5 | -0.56 | -0.06 | 12 | ||
2018-04-26 | 2018-03-31 | -0.5 | -0.56 | -0.06 | 12 | ||
2019-05-09 | 2019-03-31 | -0.47 | -0.54 | -0.07 | 14 | ||
2015-10-29 | 2015-09-30 | -0.3 | -0.23 | 0.07 | 23 | ||
2014-05-06 | 2014-03-31 | -0.34 | -0.27 | 0.07 | 20 |
Cytokinetics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Cytokinetics Stock. Current markets are slightly bearish. About 58% of major world exchanges and indexes are down. See today's market update for more information.
26th of November 2024
Disposition of 5300 shares by Malik Fady Ibraham of Cytokinetics at 7.96 subject to Rule 1... at MacroaxisInsider
20th of November 2024
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan at zacks.com
18th of November 2024
Disposition of 5000 shares by Robert Blum of Cytokinetics at 6.67 subject to Rule 16b-3 at investing.com
14th of November 2024
Significant Portfolio Addition T. Rowe Price Investment Management, Inc. ... at gurufocus.com
13th of November 2024
Cytokinetics EVP sells 370,880 in stock at investing.com
11th of November 2024
Cytokinetics reports initiation of phase 1 clinical study of CK-4015089 at seekingalpha.com
8th of November 2024
Cytokinetics, Incorporated Q3 2024 Earnings Call Transcript at insidermonkey.com
7th of November 2024
Cytokinetics Inc Q3 2024 Earnings Call Highlights Strategic Advances Amid Financial ... at finance.yahoo.com
4th of November 2024
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 at finance.yahoo.com
10th of October 2024
Cytokinetics, Incorporated CEO Sells 5,000 Shares at thelincolnianonline.com
20th of September 2024
Apellis Stock Hammered After Eye Drug Gets A Third European Rejection at investors.com
Cytokinetics Investors Sentiment
The influence of Cytokinetics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Cytokinetics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Cytokinetics' public news can be used to forecast risks associated with an investment in Cytokinetics. The trend in average sentiment can be used to explain how an investor holding Cytokinetics can time the market purely based on public headlines and social activities around Cytokinetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Cytokinetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Cytokinetics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Cytokinetics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Cytokinetics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cytokinetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cytokinetics' short interest history, or implied volatility extrapolated from Cytokinetics options trading.
Check out Cytokinetics Backtesting and Cytokinetics Hype Analysis. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.38) | Revenue Per Share 0.03 | Quarterly Revenue Growth 0.225 | Return On Assets (0.30) | Return On Equity (5.72) |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.